palopegteriparatide   Click here for help

GtoPdb Ligand ID: 13484

Synonyms: mPEG-PTH (1-34) | TransCon PTH | Yorvipath®
Approved drug
palopegteriparatide is an approved drug (EMA (2023), FDA (2024))
Compound class: Peptide
Comment: Palopegteriparatide is a synthetic parathyroid hormone mimetic prodrug. Structurally it is an N-terminally PEGylated fragment of amino acids 1-34 of the mature human peptide (84 aa) [1]. Palopegteriparatide is inactive at the PTH receptor until the peptide-PEG linker is cleaved, releasing the active PTH(1-34) peptide.
No information available.
Summary of Clinical Use Click here for help
Palopegteriparatide is a PTH replacement therapy that is authorised as a sustained-release prodrug to treat hypoparathyroidism.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT04701203 A Trial Investigating the Safety, Tolerability and Efficacy of TransCon PTH Administered Daily in Adults With Hypoparathyroidism Phase 3 Interventional Ascendis Pharma A/S
NCT05387070 PaTHway CHINA TRIAL: A Trial to Investigating the Safety, Tolerability and Efficacy of TransCon PTH in Adults With Hypoparathyroidism Phase 3 Interventional Visen Pharmaceuticals (Shanghai) Co., Ltd.
External links Click here for help
For extended ADME data see the following:

European Medicines Agency (EMA)